tapebrief
CLX · Q1 2026
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CLX · Q2 2026 Earnings

Clorox

Reported February 3, 2026

30-second summary

Organic sales fell just 1% in Q2 FY2026 — materially better than the "low single digits negative" Bellet framed last quarter — and Clorox reaffirmed every FY2026 line: net sales -6% to -10%, organic -5% to -9%, adjusted EPS $5.95-$6.30. The number behind the number: Household segment revenue still fell 6% with adjusted EBIT of just $22M on $419M of sales (5.3% margin, down 54% YoY from $48M), and management explicitly conceded it "haven't been afraid to increase the price promotion in the short term" and would make "strategic" price reductions where needed — a clean reversal of the prior posture that price discipline could hold while innovation did the work.

Headline numbers

EPS

Q2 FY2026

$1.39

Revenue

Q2 FY2026

$1.67B

-1.0% YoY

Gross margin

Q2 FY2026

43.2%

Key financials

Q2 FY2026
MetricQ2 FY2026YoYQ1 FY2026QoQ
Revenue$1.67B-1.0%$1.43B+17.1%
EPS$1.39—$0.85+63.5%
Gross margin43.2%—41.7%+150bps

Guidance

Company maintains full-year FY2026 guidance across all key metrics (GAAP EPS, adjusted EPS, net sales, organic sales, gross margin), with Q2 organic sales decline of -1% tracking better than expected and full-year trends positioned within guided ranges.

Guidance is issued for both next quarter and the full year. Both may appear below.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Organic sales growthQ2 FY2026Low single digits negative-1%Above guide (low single digits negative typically implies -2% to -9%; actual of -1% is at the better end of that range)Beat

Reaffirmed unchanged this quarter: GAAP EPS ($5.60 to $5.95), Adjusted EPS (non-GAAP) ($5.95 to $6.30), Net sales growth (Down 6% to 10%), Organic sales growth (Down 5% to 9%), Gross margin change (Down 50 to 100 basis points)

Segment performance

Q2 FY2026
SegmentQ2 FY2026YoY
Health and Wellness$0.643B+2.0%
Household$0.419B-6.0%
Lifestyle$0.321B-5.0%
Health and Wellness adjusted EBIT$190M—
Household adjusted EBIT$22M—
Lifestyle adjusted EBIT$72M—
International adjusted EBIT$31M—

Platform metrics

Q2 FY2026
SegmentQ2 FY2026
Organic sales growth-1%

Profitability

Q2 FY2026
SegmentQ2 FY2026
Adjusted EBIT (total)$256M
Operating cash flow YTD$404M

Other KPIs

Q2 FY2026
SegmentQ2 FY2026YoY
International$0.294B+7.0%

Management tone

Q4 own-goal acknowledgement → Q1 walked-back recovery confidence → Q2 price-investment capitulation.

Price discipline reversed in two quarters. At Q4 FY2025, management framed pricing as held by brand strength; at Q1 FY2026, Bellet still flagged competitive pressure but committed to innovation-led recovery. This quarter Rendle said outright: "If we need to make a price reduction that is strategic, we'll do it…we have the right tools in place to do that," and "we haven't been afraid to increase the price promotion in the short term to deal with the headwinds." That is the second-derivative tone shift of this cycle — not whether share recovers, but how it gets recovered. The path now explicitly includes promotional spend, not just innovation and execution.

Share losses reframed from "temporary" to "persistent and requiring both levers." Rendle: "our share performance was what it was supposed to be, what we expected it to be, not what we want it to be, but we were down in share." The Q4 FY2025 framing was that share would recover with innovation; the Q1 FY2026 framing conceded losses were "more than anticipated"; this quarter normalizes share loss as the expected near-term state while management funds promo to defend. The gap between "supposed to be" and "want it to be" is the new operating reality.

Promotional environment recalibrated from "back to pre-COVID" to "elevated vs historical." Q4 FY2025 framed competitive intensity as returning to pre-COVID norms; this quarter Rendle acknowledged "elevated promotion levels this year versus last year as we expected" with litter and trash specifically called out as "more competitively intense." The hedge has moved from category-level to category-specific, with the categories where Clorox is losing share being the ones running hot.

Category growth resignation hardened. Rendle: "we expect to see zero to one in the back half of the year. We don't see anything to indicate a trajectory change." That is a flat resignation — no longer a recovery thesis, just a working assumption. Coupled with her caution against reading January weather-driven scanner noise, the message is that any near-term data point pointing to acceleration should be discounted.

ERP narrative transitioning out of the spotlight. From "majority of ERP rollout now behind us" at Q1 FY2026 to forward-focused competitive strategy this quarter — Bellet noted the final phase was completed in January with implementation finishing at the end of Q3 FY2026. The ERP overhang is closing, which removes one alibi: from H2 FY2026 onward, sales trajectory has to stand on its own.

Recurring themes management leaned on this quarter:

ERP implementation stabilization and future optimization benefitsInnovation as primary growth lever for back half with delayed realizationSelective price investments and net revenue management capabilitiesConsumer bifurcation and value-seeking behavior persistenceChannel shift to club and e-commerce requiring pack size flexibilityGross margin expansion expected in back half as ERP costs normalize

Risks management surfaced:

Competitive intensity in litter and trash bag categories remains elevatedConsumer value-seeking behavior and continued channel shifting creating price mix headwindsERP optimization phase timing and magnitude of benefits uncertainCategory growth stalled at flat-to-1% with no evidence of accelerationInnovation execution risk and timing of shelf resets delayed to Q3/Q4

Answers to last quarter's watch list

Q2 FY2026 organic sales vs the "low single digits" negative guide — Q2 FY2026 organic landed at -1%, at the better end of the guided range. Reported revenue YoY of -1% matches, suggesting minimal divestiture/FX noise this quarter. The back-half ex-ERP "positive low single digits" math is now more achievable, though the H2 inflection is still anchored on innovation execution and the new wildcard of selective price investments.
Resolved positively
Gross margin Q2 FY2026 — Q2 FY2026 gross margin of 43.2% declined 60 bps YoY, squarely within the FY -50 to -100 bps guide corridor. The "nothing structural" narrative holds for a second quarter, and management framed back-half gross margin as expanding on the ex-ERP base. Status: Resolved in line
Trash and litter promotional intensity — Household segment EBIT of $22M on $419M = 5.3% margin, with EBIT down 54% YoY. Management explicitly confirmed they are funding promotional spend to defend share in litter and trash, and Rendle's "haven't been afraid to increase the price promotion" comment makes it explicit. Promo is being used to defend, EBIT is the cost.
Resolved negatively
ERP completion confirmation — Bellet confirmed the final phase was completed in January, with full implementation wrapping at the end of Q3 FY2026. No second wave of fill-rate disruption surfaced. The "we're through the hard part" framing holds.
Resolved positively
Innovation pipeline disclosure — Management still leaned on qualitative innovation language without naming specific SKUs, distribution gains, or scanner share data in the press release. "Innovation as primary growth lever for back half with delayed realization" was a tone theme. The disclosure bar has not been cleared.
Continue monitoring

What to watch into next quarter

Household segment EBIT margin trajectory: Q2 FY2026 came in at 5.3% with EBIT down 54% YoY. Further compression in Q3 FY2026 would mean promotional spend is escalating faster than share is being recaptured — i.e. promo as a structural fixture rather than a tactical bridge.

Magnitude of "selective price investments": management opened the door to strategic price reductions this quarter. Watch for an explicit dollar quantification of net revenue management headwinds in the Q3 FY2026 print, and whether the FY2026 adjusted EPS range gets narrowed downward or held.

Q3 FY2026 organic sales trajectory: the back-half "positive low single digits" ex-ERP math requires Q3 FY2026 to inflect. A Q3 FY2026 print of zero or worse on organic — with ERP no longer the alibi — invalidates the H2 recovery thesis.

Lifestyle segment continued softness: -5% in Q2 FY2026 on a cleaner comp (ERP reversal mostly behind it) is concerning. Charcoal and food/dressings carry meaningful Q4 FY2026 seasonality; watch whether Lifestyle stabilizes or extends the soft trend into Q3 FY2026.

Named innovation SKUs and distribution gains: management's back-half story rests on innovation. Without specific SKU names, ACV gains, or scanner share data at Q3 FY2026, the innovation narrative remains rhetoric.

Sources

  1. Clorox Q2 FY2026 press release, February 3 2026 — https://www.sec.gov/Archives/edgar/data/21076/000002107626000008/ex991-pressreleasedatedfeb.htm
  2. Clorox Q2 FY2026 earnings call commentary (tone, price-investment posture, category growth framing, ERP completion)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.